Vivimed Labs shines on getting approval from Uzbekistan government for two products

08 Mar 2021 Evaluate

Vivimed Labs is currently trading at Rs. 18.15, up by 0.85 points or 4.91% from its previous closing of Rs. 17.30 on the BSE.

The scrip opened at Rs. 17.40 and has touched a high and low of Rs. 18.60 and Rs. 17.40 respectively. So far 93731 shares were traded on the counter.

The BSE group 'B' stock of face value Rs. 2 has touched a 52 week high of Rs. 23.62 on 25-Aug-2020 and a 52 week low of Rs. 6.50 on 23-Mar-2020.

Last one week high and low of the scrip stood at Rs. 18.60 and Rs. 15.70 respectively. The current market cap of the company is Rs. 145.93 crore.

The promoters holding in the company stood at 32.79%, while Institutions and Non-Institutions held 3.22% and 63.99% respectively.

Vivimed Labs has received approval from the Uzbekistan government for two products. The company has received approval for Bilastin tablets, which are used for the treatment of allergic Rhino conjunctivitis and Urticaria. Vivimed has also received approval for Orzole combi, which is used to treat gastrointestinal infections such as acute diarrhoea or dysentery, gynaecological, lung and urinary infections.

Vivimed Labs is engaged in providing specialty chemicals and pharmaceuticals products. The company offers products for oral care, sun care, skin care, hair care, reversacol photochromic dyes, imaging chemicals and nisarg.

Vivimed Labs Share Price

5.75 0.00 (0.00%)
31-Jul-2023 18:02 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1523.80
Dr. Reddys Lab 5959.10
Cipla 1352.95
Zydus Lifesciences 934.50
Lupin 1599.65
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.